NASDAQ : SPRO
Spero Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.06 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 61.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 61.73M |
| Enterprise Value | 13.00M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 58.23M |
| Shares Outstanding | 58.23M |
| Shares Change (YoY) | +9.06% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 3.34% |
| Owned by Institutions (%) | 21.10% |
| Float | 47.10M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 8.30 |
| Forward PE | n/a |
| PS Ratio | 1.31 |
| Forward PS | n/a |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | 3.15 |
| P/OCF Ratio | 3.15 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 1.76 |
| EV / Sales | 0.28 |
| EV / EBITDA | n/a |
| EV / EBIT | 1.97 |
| EV / FCF | 0.66 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.12 |
| Quick Ratio | 6.03 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.25 |
| Debt / FCF | 0.10 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 19.17% |
| Return on Assets (ROA) | 7.19% |
| Return on Invested Capital (ROIC) | 32.09% |
| Return on Capital Employed (ROCE) | 14.91% |
| Weighted Average Cost of Capital (WACC) | 12.09% |
| Revenue Per Employee | $1.88M |
| Profits Per Employee | $295,320 |
| Employee Count | 25 |
| Asset Turnover | 0.82 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 261,000 |
| Effective Tax Rate | 3.41% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -54.51% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 41.20 |
| Average Volume (20 Days) | 410,670 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 840,529 |
| Short Previous Month | 794,509 |
| Short % of Shares Out | 1.44% |
| Short % of Float | 1.78% |
| Short Ratio (days to cover) | 1.00 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 47.00M |
| Gross Profit | 26.47M |
| Operating Income | 6.61M |
| Pretax Income | 7.64M |
| Net Income | 7.38M |
| EBITDA | n/a |
| EBIT | 6.61M |
| Earnings Per Share (EPS) | $0.13 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 50.77M |
| Total Debt | 2.04M |
| Net Cash | 48.73M |
| Net Cash Per Share | $0.84 |
| Equity (Book Value) | 44.20M |
| Book Value Per Share | 0.76 |
| Working Capital | 43.16M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 19.58M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | 19.58M |
| FCF Per Share | $0.34 |
Margins
| Measure | Value |
|---|
| Gross Margin | 56.31% |
| Operating Margin | 14.07% |
| Pretax Margin | 16.26% |
| Profit Margin | 15.71% |
| EBITDA Margin | n/a |
| EBIT Margin | 14.07% |
| FCF Margin | 41.66% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.06% |
| Shareholder Yield | -9.06% |
| Earnings Yield | 12.05% |
| FCF Yield | 31.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.33 |
| Price Target Difference | 403.11% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -20.87% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.68 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |